What is it?
Identity and formulation
1Pramiracetam, developed as CI-879, belongs to the synthetic racetam family. Free-base and salt identifiers do not imply identical masses. Pramistar is a medicine brand, not proof that every retail powder with the same ingredient name is an equivalent product.
A small acquired-injury study
5An older double-blind placebo-controlled study in males with memory problems after head injury or anoxia reported better memory performance, especially delayed recall. Its later 18-month phase was open-label, followed by one month off drug. That follow-up is not proof of a lasting benefit for healthy adults, and the very small clinical sample limits generalization.
Healthy volunteers under a drug challenge
9A randomized study included 24 men in two age groups. After 10 days of pramiracetam or placebo, scopolamine was used to impair memory experimentally. Pramiracetam partly reduced the induced amnesia. This design asks about resistance to a drug challenge, not better baseline cognition, and the abstract does not quantify adverse events.
A largely negative Alzheimer's trial
10In 10 patients with probable Alzheimer's disease, eight showed an apparent best dose during dose-finding, but only two improved comparably in the replication phase. The investigators concluded that doses up to 4000 mg were unlikely to provide symptomatic benefit. This negative result cautions against a general claim that higher exposure means better cognition.
Names, aliases and forms
Mechanisms of action
Cholinergic hypotheses are not a benefit guarantee
6Pramiracetam is discussed in relation to cholinergic signaling and choline handling, but its mechanism is not fully established. Mechanistic or animal findings cannot specify a useful human cognitive dose or prove that adding choline makes it work.
Potential effects and evidence map
Grade C reflects small human studies in brain injury and experimentally induced memory impairment, with mixed or negative findings in other patient research. These populations and designs do not establish useful enhancement of normal cognition. Pharmacokinetic measurements show drug exposure, not benefit.
Typical dosages and timing
The drug-challenge experiment used 600 mg twice daily for 10 days before the challenge. This research exposure is not a recommended healthy-adult dose, a powder-measuring instruction or evidence that larger doses work better.
Timing & effect horizon
The 1985 study gave 12 fasting healthy men single oral doses from 400 to 1600 mg. Plasma peaks occurred at 2-3 hours; harmonic mean elimination half-lives across dose groups were 4.5-6.5 hours. No significant side effects were observed in that small experiment. These values do not establish felt onset, cognitive-effect duration, a safe redosing interval or long-term safety.
Safety, side effects and risk profile
Country-specific medicine records do not establish unrestricted retail or import eligibility.
The cited medicine label contraindicates pregnancy and breastfeeding.
Severe renal impairment and hepatic impairment are contraindications in the cited medicine label.
The official patient leaflet lists dizziness, agitation, insomnia, nausea and upper-abdominal pain as common. Confusion and tremor are less common. These can affect daily activities even when not medically serious.
Interactions and cautions
The Pramistar label reports no demonstrated interactions with several studied medicine classes, but still cautions about anticoagulants, antiplatelets and bleeding disorders based on piracetam-class findings. Its thyroid-extract warning also comes from piracetam, not direct pramiracetam proof. These distinctions do not establish that an arbitrary stack is safe.
Legal and regulatory status
As checked October 12, 2026, the EMA list dated May 8, 2025 identifies nationally authorised Pramistar products in Latvia, Romania and Lithuania. It is not an EU-wide authorization for every product, a guarantee of current stock or permission to import a research powder into another country.
As checked October 12, 2026, the FDA orphan database lists the 1991 pramiracetam sulfate designation as withdrawn or revoked and the orphan indication as not FDA approved. A chemical substance identifier or historical designation is not a consumer-product approval. This record alone does not decide possession or import rules elsewhere.
As reviewed October 12, 2026, a 2022 United States Department of Justice enforcement release included pramiracetam among unapproved and misbranded drugs sold for consumer use. It concerns that enforcement case, not a quality assessment of the current vendors shown here, and it does not create a global possession rule.
How it compares
The cited Pramistar tablet declares 600 mg pramiracetam supplied as its sulfate salt. A powder listing should specify whether its grams describe free base, total salt or active-equivalent content. Compare only the same declared basis; do not apply a tablet count or medicine dose directly to an unspecified powder.
Practical buying and quality notes
- Use price per gram for a powder, and declared pramiracetam amount rather than tablet or capsule count alone for unit products. A medicine tablet, a single-ingredient research powder and a multi-ingredient blend are not interchangeable purchase categories. Check salt identity, region and shipping before comparing their totals.7
- Check whether a certificate matches the lot, identifies the chemical form and assay method, and reports relevant contaminants. A purity percentage without identity or batch information is weak evidence. Testing does not establish clinical suitability, and a research label is not proof of medicine approval.11
FAQ
What is the evidence-based pramiracetam dose?
9There is no validated dose for everyday cognitive enhancement in healthy adults. The displayed research amount belongs to a small drug-challenge experiment, not a general supplement recommendation. A prescription product follows its own local label and clinical context.
How long does pramiracetam last, and should it be cycled?
4Plasma The time for blood levels to fall by half during the final elimination phase.Source describes elimination, not a proven period of improved focus or memory. Human research does not define a useful healthy-user effect duration, a redosing schedule or a cycling protocol. The featured 10-day study window is exposure before a laboratory challenge, not a suggested cycle.
References
- PubChem Compound Summary for Pramiracetam, CID 51712.
- U.S. FDA Orphan Drug Designations and Approvals record for pramiracetam sulfate.
- European Medicines Agency. Pramiracetam list of nationally authorised medicinal products, PSUSA/00002492/202409.
- Chang T, Young RM, Goulet JR, Yakatan GJ. Pharmacokinetics of oral pramiracetam in normal volunteers. J Clin Pharmacol. 1985.
- McLean A Jr, Cardenas DD, Burgess D, Gamzu E. Placebo-controlled study of pramiracetam in young males with memory and cognitive problems resulting from head injury and anoxia. Brain Inj. 1991.
- Malykh AG, Sadaie MR. Piracetam and piracetam-like drugs: from basic science to novel clinical applications to CNS disorders. Drugs. 2010.
- Romanian National Agency for Medicines and Medical Devices. Pramistar 600 mg: Summary of Product Characteristics, authorization 12841/2019/01. Current posted document checked October 12, 2026.
- Romanian National Agency for Medicines and Medical Devices. Pramistar 600 mg patient leaflet. Revised August 2025.
- Mauri M, Sinforiani E, Reverberi F, Merlo P, Bono G. Pramiracetam effects on scopolamine-induced amnesia in healthy volunteers. Arch Gerontol Geriatr. 1994;18(2):133-139.
- Claus JJ, et al. Nootropic drugs in Alzheimer's disease: symptomatic treatment with pramiracetam. Neurology. 1991;41(4):570-574.
- U.S. Department of Justice. Fort Collins Couple Sentenced to Federal Prison for Illegally Selling Unapproved Drugs. June 10, 2022.